Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Breast Cancer
Intervention: Anastrozole (Drug)
Phase: N/A
Status: Completed
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
H Brasch, Study Director, Affiliation: AstraZeneca Germany
Summary
The purpose of this study is the initial/followed by 5 year adjuvant therapy with
Anastrozole.
Clinical Details
Official title: Postmenopausal Women With Early Hormone-Receptor Positive Breast Cancer/no Metastasis
Study design: Case-Only, Prospective
Primary outcome: evaluation of Anastrozole therapy as adjuvant treatment in post.menopausal women with not advanced breast cancer únder naturalistic conditions
Secondary outcome: description of population treated with anastrozolefurther information about the change of specific laboratory parameters
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Postmenopausal women with early hormone receptor positive breast cancer/no metastasis
Exclusion Criteria:
- None
Locations and Contacts
Additional Information
Starting date: May 2005
Ending date: March 2007
Last updated: March 19, 2008
|
